

# PATENT COOPERATION TREATY

## PCT

REC'D 01 JUL 2004

WIPO

PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>AREX-PWO-015</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/US03/11457</b>	International filing date (day/month/year) <b>11 April 2003 (11.04.2003)</b>	Priority date (day/month/year) <b>11 April 2002 (11.04.2002)</b>
International Patent Classification (IPC) or national classification and IPC <b>IPC(7): A61K 39/395 and US Cl.: 424/130.1, 131.1, 133.1, 138.1</b>		
Applicant <b>ALTAREX CORPORATION</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.  
☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).  
These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand <b>03 November 2003 (03.11.2003)</b>	Date of completion of this report <b>12 January 2004 (12.01.2004)</b>
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230	Authorized officer <i>Marianne Seidel</i> Marianne Seidel Telephone No. 703-308-1123

Form PCT/IPEA/409 (cover sheet)(July 1998)

BEST AVAILABLE COPY

**I. Basis of the report****1. With regard to the elements of the international application:\***☐ the international application as originally filed.☒ the description:

pages 1-67 as originally filed

pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_.☒ the claims:

pages 68-71 as originally filed

pages NONE, as amended (together with any statement) under Article 19pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_.☒ the drawings:

pages 1-9 as originally filed

pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_.☐ the sequence listing part of the description:pages NONE, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_.**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.**4. ☐ The amendments have resulted in the cancellation of:**☐ the description, pages NONE☐ the claims, Nos. NONE☐ the drawings, sheets/fig NONE**5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)

Claims 1-35 YES  
Claims NONE NO

Inventive Step (IS)

Claims 1-35 YES  
Claims NONE NO

Industrial Applicability (IA)

Claims 1-35 YES  
Claims NONE NO**2. CITATIONS AND EXPLANATIONS**

Claims 1-35 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the method for treating a patient to reduce the proliferation of and/or kill target cells that express an antigen, comprising administering one or more agents that cause apoptosis of the target cells and an antibody immunoreactive with said antigen, and wherein said antibody is cytotoxic to said target cells. Although Sykes et al(US6086873) teaches use of specific UV-exposed antibodies to increasing immune response in cancer patient, it failst to teache concurrent administration of cytotoxic agent and antibody . Thus, the novelty has not been destroyed.

Claims 1-35 meet the criteria set out in PCT Article 33(4), and thus the instant invention improves industrial applicability because the subject matter claimed can be effectively used in industry.

----- NEW CITATIONS -----